Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)

@article{Pendyala1985HumanPO,
  title={Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)},
  author={Lakshmi Pendyala and Stefan Madajewicz and Patrick Joseph Creaven},
  journal={Investigational New Drugs},
  year={1985},
  volume={3},
  pages={375-381}
}
Pharmacokinetics of CGP 15720A have been studied in patients receiving this drug in a short I.V. infusion during its phase I clinical trial. Plasma decay was biphasic with a mean t1/2β of 4.9 ± 2.47h. The drug was cleared rapidly from plasma (7.02 ± 5.95 L/h). Renal clearance (4.13 ± 1.65 L/h) appears to be the major clearance pathway. The steady state volumes of distribution of the drug indicate limited tissue distribution for the drug. Studies with plasma and urine of patients receiving 14[C… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-6 OF 6 REFERENCES

Phase I study of l-(2-[2(4-pyridyl)-2-imidozoline 1-yl]-ethyl)-3-(4-carboxyphenyl)-urea (CGP 15720A) (Abstract)

  • P Creaven, S Madajewicz, +4 authors M Cushman
  • Proc Amer Soc Clin Oncol
  • 1985
Highly Influential
3 Excerpts

Toporce JD: BMDP Statistical Software, University of California

  • MB Brown, L Engleman, JW France, MA Hill, RI Jenrich
  • Los Angeles,
  • 1981
1 Excerpt

Similar Papers

Loading similar papers…